Clinical trial • Phase III • Endocrinology
RO7795068 for Obesity | Overweight
Phase III trial of RO7795068 for Obesity | Overweight. 60 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Obesity | Overweight
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 26-03-2026
- First CTIS Authorization Date
- 15-05-2026
Trial design
Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 60
- Trial Duration For Participant
- 365
Eligibility
Recruits 60 Vulnerable population selected in Part I; no further details on the nature of the vulnerable population or consent/assent handling are provided in the supplied data..
- Vulnerable Population
- Vulnerable population selected in Part I; no further details on the nature of the vulnerable population or consent/assent handling are provided in the supplied data.
Recruitment
- Planned Sample Size
- 60
- Recruitment Window Months
- 12
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 60
Netherlands
- Earliest CTIS Part Ii Submission Date
- 05-05-2026
- Latest Decision Or Authorization Date
- 15-05-2026
- Processing Time Days
- 10
- Number Of Sites
- 1
- Number Of Participants
- 60
Sites
- Site Name
- Pharmaceutical Research Associates Group B.V.
- Department Name
- Program Management
- Contact Person Name
- Jart Oosterhaven
- Contact Person Email
- Jart.Oosterhaven@iconplc.com
Sponsor
Primary sponsor
- Full Name
- F. Hoffmann-La Roche AG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Switzerland
Investigational products
- Investigational Product Name
- RO7795068
Related trials
Other published trials that may interest you.
- LY3841136 SODIUM for Obesity | Overweight
- N-[2-(3-CYANO-5-FLUOROPHENYL)-2-METHYL-1-OXOPROPYL]-BETA-ALANYL-L-ALPHA-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-ALPHA-ASPARTYL-L-TYROSYL-L-SERYL-L-ISOLEUCYL-2-METHYLALANYL-L-LEUCYL-L-ALPHA-ASPARTYL-L-LYSYL-L-ISOLEUCYL-L-ALANYL-L-GLUTAMINYL-N6-[N-(19-CARBOXY-1-OXONONADECYL)-L-GAMMA-GLUTAMYL-2-[2-(2-AMINOETHOXY)ETHOXY]ACETYL-2-[2-(2-AMINOETHOXY)ETHOXY]ACETYL]-L-LYSYL-L-ALANYL-L-PHENYLALANYL-L-VALYL-L-GLUTAMINYL-L-TRYPTOPHYL-L-LEUCYL-L-ISOLEUCYL-L-ALANYLGLYCYLGLYCYL-L-PROLYL-L-SERYL-L-SERYLGLYCYL-L-ALANYL-L-PROLYL-L-PROLYL-L-PROLYL-L-SERINAMIDE for Obesity | Overweight
- Humanised IgG1 monoclonal antibody against human latent myostatin for Obesity | Overweight
- RO7795081 for Obesity | Overweight
- AZD9550 for Obesity | Overweight